



# Biotech Daily

Thursday May 14, 2020

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: PATRYS, MESOBLAST UP 8%  
- RESONANCE DOWN 11%**
- \* **RACE, NEWCASTLE UNI WORK ON BISANTRENE BREAST CANCER COMBO**
- \* **ANTEOTECH, AXXIN DEVELOP SEPSIS MULTIPLEX ASSAY**
- \* **NUHEARA SURPASSES 4k IQBUDS MAX PRE-ORDERS**
- \* **MACH7 \$4.8m HAHK SOFTWARE ORDER**
- \* **TELIX, FDA MEET FOR PHASE III TLX591 PROSTATE CANCER TRIAL**
- \* **EMVISION RESTARTS PORTABLE BRAIN SCANNER STROKE TRIAL**

## MARKET REPORT

The Australian stock market fell 1.72 percent on Thursday May 14, 2020, with the ASX200 down 93.2 points to 5,328.7 points.

Five of the Biotech Daily Top 40 stocks were up, 23 fell, seven traded unchanged and five were untraded. All three Big Caps fell.

Patrys was the best, up 0.1 cents or 8.33 percent to 1.3 cents, with 309,915 shares traded, followed by Mesoblast up 8.26 percent to \$3.67 with 18.9 million shares traded.

Genetic Signatures and Imugene improved more than three percent; and Dimerix rose two percent.

Resonance led the falls, down two cents or 11.1 percent to 16 cents, with 2.5 million shares traded.

Oncosil lost 8.3 percent; Optiscan fell seven percent; Avita, Clinuvel and Uscom were down six percent or more; Paradigm was down 5.4 percent; Ellex, Medical Developments, Neuren, Next Science, Polynovo and Pro Medicus fell four percent or more; LBT, Nanosonics, Opthea, Starpharma and Volpara were down three percent or more; Cochlear, CSL, Cynata, Prescient, Resmed and Telix shed more than two percent; Pharmaxis was down 1.15 percent; with Compumedics down by 0.9 percent.

## RACE ONCOLOGY

Race says it will work with the University of Newcastle to identify combinations of current breast cancer drugs with Bisantrone to reduce side effects.

Last November, Race said it was planning a US phase II trial of Bisantrone for acute myeloid leukemia and proof-of-concept phase I/II trials of Bisantrone for combination treatments of breast and ovarian cancer in Australia as part of a five-path clinical strategy (BD: Nov 14, 2019).

Today, the company said the research aimed to find a combination that showed equivalent efficacy and significantly reduced the side effects.

Race said that current breast cancer treatments potentially resulted in side effects, such as life-long damage to the patient's heart.

The company said that "many breast cancer patients are cured of their cancers only to later die of treatment-induced heart failure".

Race said that a phase III single agent trial of Bisantrone for advanced breast cancer in the late 1980s and early 1990s showed that Bisantrone had the same efficacy as the standard of care, doxorubicin, but caused significantly less damage to the heart.

The company said intellectual property from the research program would be wholly owned by the company and the results would support a phase I/IIa human trial of Bisantrone for breast cancer, currently scheduled to begin in Australia in late 2020.

Race was up 1.5 cents or 4.4 percent to 35.5 cents.

## ANTEOTECH (FORMERLY ANTEO DIAGNOSTICS)

Anteotech says that it has developed a multiplex assay test for high sensitivity detection and rapid diagnosis of sepsis with the Melbourne-based Axxin.

Last year, Anteotech said it would work with Axxin to develop a model assay using its particle conjugation diagnostic Anteobind on Axxin's Gen 3 readers (BD: Sep 25, 2019).

Today, the company said it had used its Anteobind to conjugate three antibodies, anti-procalcitonin (anti-PCT), anti-interleukin 6 (anti-IL-6) and anti-C-reactive protein (anti-CRP), into a single particle to allow the test to function at high reproducibility and specificity and to minimise the volume of patient samples required.

Anteotech said it had completed all lateral flow full-strip elements of test development and had delivered a high-sensitivity quantitative platform, which used its Anteobind activated Europium particles in the conjugation process.

The company said it tested the detection response using a serum that used the Axxin AX-2X-S lateral flow reader for high sensitivity detection of sepsis and it was within range as a clinically relevant biomarker for sepsis.

Anteotech said the test would require further work to optimize the conjugation and signal response and to develop algorithms using the quantitative data to add value to clinical patient decision support.

The company said it would move to full clinical trials, regulatory approvals and commercialization.

Anteotech chief executive officer Derek Thomson said the "collaborative relationship between Axxin and Anteotech has strengthened considerably through this program". "We have proven that we can develop an end-to-end solution for high sensitivity detection of a common condition and this bodes very well for future opportunities in high sensitivity point of care assay development," Mr Thomson said.

"For Anteotech, the completion of this test is an important milestone as we rapidly progress up the point of care value chain," Mr Thomson said.

Anteotech was up 0.2 cents or 9.1 percent to 2.4 cents with 1.6 million shares traded.

## [NUHEARA](#)

Nuheara says it has received more than 4,000 pre-orders for its Iqbuds Max hearing and sound filtering earbuds.

Nuheara chief executive officer Justin Miller said that pre-orders were predominantly from Europe and North America, which made up 70 percent of all sales.

“The fact that we have built a global online platform to reach our consumers directly, and that we have now sold more than 4,000 Iqbuds Max in just four months, demonstrates how relevant and resilient our sales and marketing strategies are – even in economies drastically impacted by Covid-19,” Mr Miller said.

“In contrast, major hearing aid companies have seen sales drop by up to 80 percent in April because of the global shuttering of the economy and their subsequent inability to service customers face-to-face,” Mr Miller said.

Nuheara was up 0.2 cents or 9.1 percent to 2.4 cents with 19.3 million shares traded.

## [MACH7 TECHNOLOGIES](#)

Mach7 says it has a \$4.8 million software licence order from the Hospital Authority Hong Kong (HAHK) for its enterprise imaging data management software.

Mach7 said that it entered a five year \$HK81 million (\$A16.2 million) contract with the Authority in October 2018 to provide the software system and had received \$HK41 million in orders to date.

Mach7 was up five cents or 8.7 percent to 62.5 cents with 2.2 million shares traded.

## [TELIX PHARMACEUTICALS](#)

Telix says it will meet with the US Food and Drug Administration to discuss a phase III trial of TLX591 for men with metastatic castrate-resistant prostate cancer.

Telix said the FDA had granted it a type B pre-investigational new drug meeting, scheduled for July 7, 2020.

The company said the trial would examine the effectiveness of TLX591 in combination with best standard care, compared with best standard care alone.

Telix said the trial would recruit patients in Australia and the US, subject to approvals.

Telix chief executive officer Dr Chris Behrenbruch said the company had “spent many months” preparing for the meeting request and following the meeting would provide details on the development strategy.

“Our preparation for this meeting and the design of the Prostact trial has been conducted in close consultation with an advisory board comprising leading US, European and Australian urologic oncology experts and trialists,” Dr Behrenbruch said.

Telix fell four cents or 2.85 percent to \$1.365.

## [EMVISION MEDICAL DEVICES](#)

Emvision says it has restarted enrolment of the six-month pilot trial of its portable brain scanner for stroke patients at Brisbane’s Princess Alexandra Hospital.

Last month, Emvision said the Covid-19 pandemic had halted enrolment at 15 of 30 patients (BD: April 3, 2020).

Emvision fell seven cents or 7.7 percent to 84.5 cents.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053  
email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily**